Relay Therapeutics, Inc.
RLAY
$2.82
-$0.29-9.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 14.56% | -15.91% | |||
| Gross Profit | -2.64% | 15.91% | |||
| SG&A Expenses | -8.82% | 4.06% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.91% | -11.82% | |||
| Operating Income | 0.13% | 11.82% | |||
| Income Before Tax | -1.40% | 13.73% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1.40% | 13.73% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.40% | 13.73% | |||
| EBIT | 0.13% | 11.82% | |||
| EBITDA | -0.02% | 11.95% | |||
| EPS Basic | -0.26% | 27.71% | |||
| Normalized Basic EPS | -0.25% | 27.71% | |||
| EPS Diluted | -0.26% | 27.71% | |||
| Normalized Diluted EPS | -0.25% | 27.71% | |||
| Average Basic Shares Outstanding | 1.13% | 19.33% | |||
| Average Diluted Shares Outstanding | 1.13% | 19.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||